BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11836582)

  • 1. Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin.
    Indrová M; Bubeník J; Mikysková R; Vonka V; Smahel M; Zák R; Símová J; Bieblová J; Mendoza L; Jandlová T
    Int J Oncol; 2002 Mar; 20(3):643-6. PubMed ID: 11836582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.
    Mikysková R; Indrová M; Símová J; Jandlová T; Bieblová J; Jinoch P; Bubeník J; Vonka V
    Int J Oncol; 2004 Jan; 24(1):161-7. PubMed ID: 14654953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
    Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
    Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
    Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
    Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours.
    Indrová M; Bieblová J; Jandlová T; Vonka V; Pajtasz-Piasecka E; Reinis M
    Int J Oncol; 2006 Jan; 28(1):253-9. PubMed ID: 16328003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant cytokine treatment of minimal residual disease after surgical therapy in mice carrying HPV16-associated tumours: cytolytic activity of spleen cells from tumour regressors.
    Indrová M; Mikysková R; Jandlová T; Vonka V; Bubeník J; Bieblová J
    Folia Biol (Praha); 2003; 49(6):217-22. PubMed ID: 14748435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local IFN-gamma therapy of HPV16-associated tumours.
    Mikysková R; Bieblová J; Símová J; Indrová M; Jandlová T; Vonka V; Smahel M; Bubeník J; Mendoza L
    Folia Biol (Praha); 2003; 49(1):26-32. PubMed ID: 12630665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MHC class I+ and class I- HPV16-associated tumours expressing the E7 oncoprotein do not cross-react in immunization/challenge experiments.
    Símová J; Mikysková R; Vonka V; Bieblová J; Bubeník J; Jandlová T
    Folia Biol (Praha); 2003; 49(6):230-4. PubMed ID: 14748438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
    Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
    Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases.
    Mikysková R; Bubenik J; Mendoza L; Vonka V; Smahel M; Símová J; Jandlová T
    Clin Exp Metastasis; 2000; 18(7):581-7. PubMed ID: 11688963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 2 gene therapy of surgical minimal residual tumour disease: characterization of cytolytic effector cells from tumour progressors and regressors.
    Hájková R; Indrová M; Jandlová T; Bubeník J; Reinis M
    Folia Biol (Praha); 1999; 45(6):227-31. PubMed ID: 10732718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of tumor progression by transcriptional profiling of mouse MK16 cell lines transformed with human papillomavirus type 16 E6 and E7 oncogenes and activated H-ras.
    Smahel M; Smahelová J; Tejklová P; Tachezy R; Jelínek F
    Oncol Rep; 2005 Dec; 14(6):1665-74. PubMed ID: 16273273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Live cell vaccines expressing B7.1, monocyte chemoattractant protein 1 and granulocyte-macrophage colony stimulation factor derived from mouse HPV16-transformed cells.
    Lakatosová-Andelová M; Jinoch P; Dusková M; Marinov I; Vonka V
    Int J Oncol; 2008 Jan; 32(1):265-71. PubMed ID: 18097567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy and immunotherapy of tumours induced by gene-modified HPV16-transformed cells.
    Sobotková E; Dusková M; Smahel M; Holán V; Janousková O; Vonka V
    Oncol Rep; 2004 Oct; 12(4):877-83. PubMed ID: 15375516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16.
    Smahel M; Sobotková E; Bubeník J; Símová J; Zák R; Ludviková V; Hájková R; Kovarík J; Jelínek F; Povýsil C; Marinov J; Vonka V
    Br J Cancer; 2001 Feb; 84(3):374-80. PubMed ID: 11225590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16.
    Bubeník J; Símová J; Hájková R; Sobota V; Jandlová T; Smahel M; Sobotková E; Vonka V
    Int J Oncol; 1999 Mar; 14(3):593-7. PubMed ID: 10024696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic, therapeutic and anti-metastatic effects of BMDC and DC lines in mice carrying HPV 16-associated tumours.
    Mendoza L; Bubeník J; Símová J; Jandlová T; Vonka V; Mikysková R
    Int J Oncol; 2003 Jul; 23(1):243-7. PubMed ID: 12792800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissimilar anti-tumour reactions induced by tumour cells engineered with the interleukin-2 or interleukin-15 gene in nude mice.
    Di Carlo E; Meazza R; Basso S; Rosso O; Comes A; Gaggero A; Musiani P; Santi L; Ferrini S
    J Pathol; 2000 Jun; 191(2):193-201. PubMed ID: 10861581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer cells play a role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro.
    Kijima M; Saio M; Oyang GF; Suwa T; Miyauchi R; Kojima Y; Imai H; Nakagawa J; Nonaka K; Umemura N; Nishimura T; Takami T
    Int J Oncol; 2005 Mar; 26(3):679-84. PubMed ID: 15703823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peritumoral administration of antigen-unstimulated bone marrow-derived dendritic cells inhibits tumour growth.
    Mendoza L; Indrová M; Hájková R; Reinis M; Smahel M; Vonka V; Bubeník J; Jandlová T
    Folia Biol (Praha); 2000; 46(3):91-7. PubMed ID: 10925779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.